Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
US8962332B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8962332-B2 |
| Application number | US-201314025951-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 13, 2013 |
| Priority date | Dec 17, 2001 |
| Publication date | Feb 24, 2015 |
| Grant date | Feb 24, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a non-naturally occurring recombinant adeno-associated virus (AAV) comprising an AAV8 capsid comprising a vp1, vp2, and a vp3 protein, wherein said vp1 protein has an amino acid sequence which is at least about 95% identical to amino acids 1 to 737 of SEQ ID NO: 2, said composition further comprising a pharmaceutically acceptable carrier. 2. The composition according to claim 1 , wherein said vp1 protein has…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.